In a study by Cree, circulating tumor cells, tumor DNA, and other protein markers reportedly enabled physicians to use liquid biopsy for the detection and monitoring of actionable RASSF1A mutations in patients with lung cancer [39]. The gene discussed is RASSF1; the disease is lung carcinoma.